Original Research
Published on 18 Jul 2022
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2022.890376
- 4,772 views
- 6 citations

